Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07064538 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Neuralli® MP on Self-Defined Outcomes in Adults With Autistic Traits

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description revisedv7
  2. Trial status: Enrolling by Invitation to Active, Not Recruiting
    • Primary completion date changed from estimate of Jun 30, 2026 to Apr 30, 2026
    • Study description expanded, about 33 words
    v6
  3. Trial status: Not Yet Recruiting to Enrolling by Invitation
    • Start date changed from estimate of Aug 15, 2025 to Aug 19, 2025
    • Site contact updated
    v5
  4. Collaborators expanded, about 4 wordsv4
  5. Collaborators shortened, about 4 wordsv3
  6. Study description expanded, about 1 wordv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy of Neuralli® MP in improving participant-defined outcomes in adults with autistic traits.
Trial Details
NCT Number NCT07064538
Lead Sponsor Mackay Memorial Hospital
Collaborators: Bened Biomedical Co., Ltd.
Conditions
(from sponsor)		 ASD, Autism, Autistic Disorders Spectrum
Related terms Autistic Disorder, Child Development Disorders, Pervasive
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov